CN110960436A - Skin care composition, eye cream and preparation method thereof - Google Patents
Skin care composition, eye cream and preparation method thereof Download PDFInfo
- Publication number
- CN110960436A CN110960436A CN201911024883.9A CN201911024883A CN110960436A CN 110960436 A CN110960436 A CN 110960436A CN 201911024883 A CN201911024883 A CN 201911024883A CN 110960436 A CN110960436 A CN 110960436A
- Authority
- CN
- China
- Prior art keywords
- phase
- root extract
- extract
- eye cream
- mixing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006071 cream Substances 0.000 title claims abstract description 90
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000000284 extract Substances 0.000 claims abstract description 71
- 239000000419 plant extract Substances 0.000 claims abstract description 31
- YDSVPIYLRFZLAT-UHFFFAOYSA-N C(C)(=O)O.C(C)(=O)O.NC(CCC(=O)NCC1=CC=CC=C1)N Chemical compound C(C)(=O)O.C(C)(=O)O.NC(CCC(=O)NCC1=CC=CC=C1)N YDSVPIYLRFZLAT-UHFFFAOYSA-N 0.000 claims abstract description 20
- 108010016626 Dipeptides Proteins 0.000 claims abstract description 20
- 239000009636 Huang Qi Substances 0.000 claims abstract description 19
- 239000001180 angelica archangelica l. root extract Substances 0.000 claims abstract description 15
- 239000001649 glycyrrhiza glabra l. absolute Substances 0.000 claims abstract description 13
- 229940051810 licorice root extract Drugs 0.000 claims abstract description 13
- 235000020725 licorice root extract Nutrition 0.000 claims abstract description 13
- 241000830535 Ligustrum lucidum Species 0.000 claims abstract description 12
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 11
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 11
- XXRYFVCIMARHRS-UHFFFAOYSA-N propan-2-yl n-dimethoxyphosphorylcarbamate Chemical compound COP(=O)(OC)NC(=O)OC(C)C XXRYFVCIMARHRS-UHFFFAOYSA-N 0.000 claims abstract description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 63
- 238000002156 mixing Methods 0.000 claims description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 40
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical group NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 26
- -1 alkyl glycoside Chemical class 0.000 claims description 22
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 21
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 21
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 21
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 13
- 229960000458 allantoin Drugs 0.000 claims description 13
- 239000003906 humectant Substances 0.000 claims description 11
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical group CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 10
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 10
- 229920001577 copolymer Polymers 0.000 claims description 10
- 239000003974 emollient agent Substances 0.000 claims description 10
- 239000003995 emulsifying agent Substances 0.000 claims description 10
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 10
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 10
- 239000002562 thickening agent Substances 0.000 claims description 10
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical group OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 9
- OQILCOQZDHPEAZ-UHFFFAOYSA-N Palmitinsaeure-octylester Natural products CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 claims description 9
- JPDHZHZDXCSZAT-UHFFFAOYSA-N [3-octanoyloxy-2-[[3-octanoyloxy-2,2-bis(octanoyloxymethyl)propoxy]methyl]-2-(octanoyloxymethyl)propyl] octanoate Chemical compound CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)(COC(=O)CCCCCCC)COCC(COC(=O)CCCCCCC)(COC(=O)CCCCCCC)COC(=O)CCCCCCC JPDHZHZDXCSZAT-UHFFFAOYSA-N 0.000 claims description 9
- 239000012752 auxiliary agent Substances 0.000 claims description 9
- GJQLBGWSDGMZKM-UHFFFAOYSA-N ethylhexyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(CC)CCCCC GJQLBGWSDGMZKM-UHFFFAOYSA-N 0.000 claims description 9
- 229960005323 phenoxyethanol Drugs 0.000 claims description 9
- 229940042585 tocopherol acetate Drugs 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 241001506047 Tremella Species 0.000 claims description 6
- 239000013538 functional additive Substances 0.000 claims description 5
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 claims description 4
- 239000000043 antiallergic agent Substances 0.000 claims description 4
- 229940031674 laureth-7 Drugs 0.000 claims description 4
- 229920002401 polyacrylamide Polymers 0.000 claims description 4
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 claims description 3
- 240000000559 Albizia odoratissima Species 0.000 claims description 3
- 235000011438 Albizia odoratissima Nutrition 0.000 claims description 3
- 235000003880 Calendula Nutrition 0.000 claims description 3
- 240000001432 Calendula officinalis Species 0.000 claims description 3
- 241000305491 Gastrodia elata Species 0.000 claims description 3
- 241001180876 Saposhnikovia Species 0.000 claims description 3
- 229940099583 aluminum starch octenylsuccinate Drugs 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 239000003899 bactericide agent Substances 0.000 claims description 3
- 229930182470 glycoside Natural products 0.000 claims description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 3
- 239000004973 liquid crystal related substance Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000003607 modifier Substances 0.000 claims description 3
- YLGYACDQVQQZSW-UHFFFAOYSA-N n,n-dimethylprop-2-enamide Chemical compound CN(C)C(=O)C=C YLGYACDQVQQZSW-UHFFFAOYSA-N 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- 229940104261 taurate Drugs 0.000 claims description 3
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 2
- 240000008917 Glycyrrhiza uralensis Species 0.000 claims description 2
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 claims description 2
- 229940008099 dimethicone Drugs 0.000 claims description 2
- 229940064222 panax notoginseng root extract Drugs 0.000 claims description 2
- 239000004909 Moisturizer Substances 0.000 claims 2
- 230000001333 moisturizer Effects 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 230000037394 skin elasticity Effects 0.000 abstract description 7
- 230000037303 wrinkles Effects 0.000 abstract description 6
- 230000003020 moisturizing effect Effects 0.000 abstract description 4
- 244000131316 Panax pseudoginseng Species 0.000 abstract description 3
- 230000035515 penetration Effects 0.000 abstract description 3
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract description 2
- 229940107131 ginseng root Drugs 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 38
- 210000003491 skin Anatomy 0.000 description 35
- 239000002994 raw material Substances 0.000 description 27
- 238000012360 testing method Methods 0.000 description 24
- 238000001816 cooling Methods 0.000 description 18
- 238000010438 heat treatment Methods 0.000 description 18
- 238000003756 stirring Methods 0.000 description 18
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 15
- 238000000926 separation method Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 230000035699 permeability Effects 0.000 description 8
- NMUKKQFFBNEVJY-UHFFFAOYSA-K 4-O-bis[(4-oct-1-enoxy-4-oxobutanoyl)oxy]alumanyl 1-O-oct-1-enyl butanedioate Chemical compound [Al+3].CCCCCCC=COC(=O)CCC([O-])=O.CCCCCCC=COC(=O)CCC([O-])=O.CCCCCCC=COC(=O)CCC([O-])=O NMUKKQFFBNEVJY-UHFFFAOYSA-K 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- HWGKTCLOBSICTE-UHFFFAOYSA-N [3-decanoyloxy-2-[[3-decanoyloxy-2,2-bis(decanoyloxymethyl)propoxy]methyl]-2-(decanoyloxymethyl)propyl] decanoate Chemical compound CCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCC)(COC(=O)CCCCCCCCC)COCC(COC(=O)CCCCCCCCC)(COC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC HWGKTCLOBSICTE-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- BQMNFPBUAQPINY-UHFFFAOYSA-N azane;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonic acid Chemical compound [NH4+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C BQMNFPBUAQPINY-UHFFFAOYSA-N 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 6
- 229910021641 deionized water Inorganic materials 0.000 description 6
- 238000004945 emulsification Methods 0.000 description 6
- 238000000265 homogenisation Methods 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 210000001015 abdomen Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 241000735234 Ligustrum Species 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 241000628997 Flos Species 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000001153 anti-wrinkle effect Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 2
- 241001135917 Vitellaria paradoxa Species 0.000 description 2
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 229940057910 shea butter Drugs 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- QGGBBQJHVCVVKM-XOBYPWAZSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-amino-3-carboxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amin Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(N)=O QGGBBQJHVCVVKM-XOBYPWAZSA-N 0.000 description 1
- AJLNZWYOJAWBCR-OOPVGHQCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O AJLNZWYOJAWBCR-OOPVGHQCSA-N 0.000 description 1
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- KGKQNDQDVZQTAG-UHFFFAOYSA-N 8-methylnonyl 2,2-dimethylpropanoate Chemical compound CC(C)CCCCCCCOC(=O)C(C)(C)C KGKQNDQDVZQTAG-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- BYUQATUKPXLFLZ-UIOOFZCWSA-N CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 BYUQATUKPXLFLZ-UIOOFZCWSA-N 0.000 description 1
- 240000001548 Camellia japonica Species 0.000 description 1
- 241000190633 Cordyceps Species 0.000 description 1
- 241001264174 Cordyceps militaris Species 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 235000008597 Diospyros kaki Nutrition 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 241000825107 Hierochloe Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 239000008681 Phellinus linteus extract Substances 0.000 description 1
- 239000009759 San-Chi Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000121220 Tricholoma matsutake Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229940095094 acetyl hexapeptide-8 Drugs 0.000 description 1
- 229940078033 acetyl octapeptide-3 Drugs 0.000 description 1
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- 229940082463 angelica sinensis root extract Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 description 1
- 229940022757 asiaticoside Drugs 0.000 description 1
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 210000001268 chyle Anatomy 0.000 description 1
- 235000018597 common camellia Nutrition 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 229940093441 palmitoyl oligopeptide Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940064064 purslane extract Drugs 0.000 description 1
- 229940084038 salix alba bark extract Drugs 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229940047670 sodium acrylate Drugs 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000001243 zingiber officinale rosc. root absolute Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/645—Proteins of vegetable origin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to a skin care composition, eye cream and a preparation method thereof. The skin care composition comprises the following components in percentage by mass (0.1-7): (1-7): (1-7) the hydrolyzed avenin, dipeptide diaminobutyrylbenzylamide diacetate, and plant extracts comprising angelica root extract, notoginseng root extract, astragalus membranaceus root extract, ligustrum lucidum ait seed extract, and licorice root extract. The skin care composition is formed by matching plant extracts containing angelica root extract, pseudo-ginseng root extract, astragalus membranaceus root extract, glossy privet seed extract and licorice root extract with oat protein and dipeptide diaminobutyrylbenzylamide diacetate in a proper proportion. The applicant finds that the eye cream prepared by the skin care composition has strong penetration effect, can play a role in deep moisturizing, and can also enable eye skin to be fine, compact and moist, improve skin elasticity and reduce wrinkles.
Description
Technical Field
The invention relates to the field of daily chemical industry, in particular to a skin care composition, eye cream and a preparation method thereof.
Background
Eye care is very important in facial care, so many eye care products are emerging, such as: an eye cream containing Cordyceps militaris component contains hydrolyzed oat protein, Cordyceps extract, herba Portulacae extract, folium kaki extract, pericarpium Citri Tangerinae extract, Scutellariae radix extract, Phellinus Linteus extract, white willow bark extract, herb Hierochloes Adoratae extract, flos Rosae Rugosae extract, semen Phaseoli Radiati extract, green tea extract, Tricholoma matsutake extract, Ginseng radix extract, radix astragali extract, radix Rhodiolae extract, radix Arnebiae extract, flos Matricariae Chamomillae extract, tree moss extract, flos Lonicerae extract, and asiaticoside. For another example: a natural anti-wrinkle eye cream comprises a natural anti-wrinkle and wrinkle-removing composition, water, polydimethylsiloxane, shea butter, caprylic/capric triglyceride, squalane, isodecyl pivalate, cetostearyl alcohol, an emulsifier and a humectant, wherein the raw materials of the natural anti-wrinkle and wrinkle-removing composition comprise sodium hyaluronate, palmitoyl tripeptide-1, bioglycan-1, purslane extract, hydrolyzed oat protein, mulberry root extract, bisabolol, ginger root extract and tocopherol acetate. Also for example: an eye essence comprises water, disodium EDTA, butanediol, betaine, allantoin, carbomer, xanthan gum, sodium acrylate copolymer and lecithin; caprylic/capric triglyceride, shea butter, camellia seed oil, olive oil, a mixture of cetyl alcohol and cetearyl glucoside, cetearyl alcohol, tocopherol (vitamin E); arginine; p-hydroxyacetophenone, 1, 2-hexanediol, butanediol; hydrolyzed coffee yellow sunflower extract, acetyl hexapeptide-8, acetyl octapeptide-3, dipeptide diaminobutyryl benzylamide diacetate. The effectiveness of these conventional eye creams is often focused on wrinkle resistance, however deep eye moisturization is also critical.
Disclosure of Invention
Based on this, it is a primary object of the present invention to provide a skin care composition. The eye cream prepared from the skin care composition has good permeability, and can deeply moisturize.
The invention provides a skin care composition, which comprises the following components in percentage by mass (0.1-7): (1-7): (1-7) the hydrolyzed avenin, dipeptide diaminobutyrylbenzylamide diacetate, and plant extract, wherein the plant extract comprises angelica root extract, notoginseng root extract, astragalus membranaceus root extract, ligustrum lucidum ait seed extract, and licorice root extract.
In one embodiment, the skin care composition comprises the following components in a mass ratio of (0.8-7): (1-6): (1-7) hydrolyzed oat protein, dipeptide diaminobutyrylbenzylamide diacetate, and plant extract.
In one embodiment, the skin care composition comprises the following components in a mass ratio of (4-7): (2-5): (1-4) hydrolyzed oat protein, dipeptide diaminobutyrylbenzylamide diacetate, and plant extract.
In one embodiment, the plant extract comprises (1-5) by mass: (3-8): (5-10): (2-6): (8-12) Angelica sinensis root extract, Panax notoginseng root extract, Astragalus membranaceus root extract, Ligustrum lucidum seed extract, and Glycyrrhiza uralensis root extract.
The invention also aims to provide application of the skin care composition in preparing skin care products.
In one embodiment, the skin care product is an eye cream.
The invention further aims to provide eye cream which comprises water and the following components in percentage by mass:
in one embodiment, the other functional auxiliary agents comprise the following components in percentage by mass:
in one embodiment, the antioxidant is tocopheryl acetate; the preservative is phenoxyethanol; or/and the anti-allergy agent is at least one of astragalus membranaceus root extract, divaricate saposhnikovia root extract, calendula extract, albizia flower extract and gastrodia elata root extract; or/and the bactericide is allantoin.
In one embodiment, the emulsifier is an alkyl glycoside type liquid crystal emulsifier; or/and the emollient is selected from at least one of polydimethylsiloxane, ethylhexyl palmitate, dipentaerythritol hexacaprylate/hexadecanoate, cyclopentadimethylsiloxane, stearyloxymethylsiloxane/polydimethylsiloxane copolymer, polydimethylsiloxane alcohol and cyclopentadimethylsiloxane; or/and the skin feel modifier is aluminum starch octenyl succinate.
In one embodiment, the humectant is selected from at least one of sodium hyaluronate, butylene glycol, propylene glycol, and Tremella extract; or/and the thickening agent is selected from at least one of acryloyl dimethyl ammonium taurate/VP copolymer and polyacrylamide, C13-14 isoparaffin and laureth-7.
Still another object of the present invention is to provide a method for preparing the above eye cream, comprising the steps of:
(1) mixing the emulsifier and part of the emollient to prepare a phase A; taking part of the other functional auxiliary agents to prepare a phase B;
(2) adding the phase B to the phase A and mixing;
(3) mixing water, part of the humectant, part of the thickener and the other functional auxiliary agent to prepare a phase C; adding the phase C into the product obtained in the step (2), and mixing;
(4) mixing the rest of the emollient and the rest of the thickener to prepare a phase D; adding the phase D into the product obtained in the step (3), and mixing;
(5) mixing the skin feeling regulator and the other part of the humectant to prepare phase E; mixing the skin care composition, the rest of the humectant and the other functional additives to prepare a phase F; mixing the rest of the other functional additives to prepare a G phase; adding the phase E, the phase F and the phase G to the product obtained in the step (4), and mixing.
Compared with the prior art, the invention has the following beneficial effects:
the skin care composition is formed by matching plant extracts containing angelica root extract, pseudo-ginseng root extract, astragalus membranaceus root extract, glossy privet seed extract and licorice root extract with hydrolyzed oat protein and dipeptide diaminobutyrylbenzylamide diacetate in a proper proportion. The eye cream prepared from the skin care composition has strong penetration effect, and can play a role in deep moisturizing. The applicant also finds that the eye cream can enable eye skin to be fine, compact and moist, improve skin elasticity and reduce wrinkles.
Detailed Description
In order that the invention may be more fully understood, reference will now be made to the following description. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used herein, the term "and/or" includes any and all combinations of one or more of the associated listed items.
The embodiment of the invention provides a skin care composition, which comprises the following components in percentage by mass (0.1-7): (1-7): (1-7) the hydrolyzed avenin, dipeptide diaminobutyrylbenzylamide diacetate, and plant extracts comprising angelica root extract, notoginseng root extract, astragalus membranaceus root extract, ligustrum lucidum seed extract, and licorice root extract.
Preferably, the skin care composition comprises the following components in a mass ratio of (0.8-7): (1-6): (1-7) hydrolyzed oat protein, dipeptide diaminobutyrylbenzylamide diacetate, and plant extract.
Preferably, the skin care composition comprises the following components in a mass ratio of (4-7): (2-5): (1-4) hydrolyzed oat protein, dipeptide diaminobutyrylbenzylamide diacetate, and plant extract.
Preferably, the plant extract comprises the following components in a mass ratio of (1-5): (3-8): (5-10): (2-6): (8-12) the angelica root extract, the notoginseng root extract, the astragalus membranaceus root extract, the privet seed extract, and the licorice root extract.
The embodiment of the invention also provides application of the skin care composition in preparing a skin care product.
Preferably, the skin care product is an eye cream.
The embodiment of the invention also provides eye cream which comprises water and the following components in percentage by mass:
preferably, the other functional auxiliary agents comprise the following components in percentage by mass:
preferably, the antioxidant is tocopherol acetate; the preservative is phenoxyethanol; or/and the anti-allergy agent is at least one of astragalus membranaceus root extract, divaricate saposhnikovia root extract, calendula extract, albizia flower extract and gastrodia elata root extract; or/and the bactericide is allantoin. The anti-allergy agent of the embodiment of the invention can be preferably selected.
Preferably, the emulsifier is an alkyl glycoside liquid crystal type emulsifier (Montanov 202); or/and the emollient is selected from at least one of polydimethylsiloxane, ethylhexyl palmitate, dipentaerythritol hexacaprylate/hexadecanoate, cyclopentadimethylsiloxane, stearyloxymethylsiloxane/polydimethylsiloxane copolymer, polydimethylsiloxane, dimethicone alcohol, and cyclopentadimethylsiloxane; or/and the skin feel modifier is aluminum starch octenyl succinate.
Preferably, the humectant is selected from at least one of sodium hyaluronate, butanediol, propylene glycol and tremella extract; or/and the thickening agent is selected from at least one of acryloyl dimethyl ammonium taurate/VP copolymer and polyacrylamide, C13-14 isoparaffin and laureth-7.
The embodiment of the invention also provides a preparation method of the eye cream, which comprises the following steps:
(1) mixing the emulsifier and part of the emollient to prepare a phase A; taking part of the other functional auxiliary agents to prepare a phase B;
(2) adding the phase B to the phase A and mixing;
(3) mixing water, part of the humectant, part of the thickener and the other functional auxiliary agent to prepare a phase C; adding the phase C into the product obtained in the step (2), and mixing;
(4) mixing the rest of the emollient and the rest of the thickener to prepare a phase D; adding the phase D into the product obtained in the step (3), and mixing;
(5) mixing the skin feeling regulator and the other part of the humectant to prepare phase E; mixing the skin care composition, the rest of the humectant and the other functional additives to prepare a phase F; mixing the rest of the other functional additives to prepare a G phase; adding the phase E, the phase F and the phase G to the product obtained in the step (4), and mixing.
The raw materials involved in the embodiments of the present invention are all commercially available raw materials, for example: hydrolyzed oat protein and plant extracts were purchased from vast forest east. The emollient adopts GI CD-9 (containing 87.0-91.0 parts of cyclopentadimethylsiloxane, 9.0-10.0 parts of stearyloxymethylsiloxane/polydimethylsiloxane copolymer and 1.0-2.0 parts of polydimethylsiloxane) and PMX-1403 (containing polydimethylsiloxane and dimethiconol); the thickener is SEPIGEL 305 (containing polyacrylamide, C13-14 isoparaffin and laureth-7).
Example 1
The embodiment provides eye cream and a preparation method thereof.
The eye cream comprises the following components in percentage by mass (see table 1):
phase A: montanov 2021.50%, polydimethylsiloxane 1.00%, ethylhexyl palmitate 3.00%, dipentaerythritol hexacaprylate/hexacaprate 0.80%;
phase B: 1.00% of tocopherol acetate;
and C phase: deionized water (to 100%), sodium hyaluronate 0.10%, ammonium acryloyldimethyl taurate/VP copolymer 0.50%, allantoin 0.06%, butanediol 3.00%, propylene glycol 3.00%;
phase D: GI CD-90.80%, PMX-14033.00%, SEPIGEL 3052.00%, cyclopentadimethylsiloxane 4.00%;
phase E: 0.50% of starch aluminum octenyl succinate and 2.00% of propylene glycol;
and (3) phase F: hydrolyzed oat protein 7.00%, dipeptide diaminobutyrylbenzylamide diacetate 2.00%, plant extract 1.00%, Irriguard (good schumann) 2.00%, and white fungus extract 0.30%; in the embodiment, the plant extract is prepared by mixing the following components in a mass ratio of 1: 3: 5: 2: 8, a combination of angelica root extract, notoginseng root extract, astragalus membranaceus root extract, privet seed extract and licorice root extract;
phase G: 0.80 percent of phenoxyethanol and 0.15 percent of essence.
The preparation method of the eye cream comprises the following steps:
(1) uniformly mixing the raw materials of the phase A component, heating to 78 ℃, stirring and melting into liquid, and preserving heat for later use;
(2) in the phase C component, after the powdery raw materials are uniformly dispersed by butanediol and propylene glycol, adding water and stirring, heating to 80 ℃ until the powdery raw materials are completely and uniformly dissolved, preserving heat and defoaming for later use;
(3) adding the phase B component into the phase A component, and heating to 80 ℃;
(4) starting homogenization, slowly adding the phase C component into the mixed component of the phase A and the phase B, homogenizing at 2500r/min for 5 minutes until complete and uniform emulsification is realized, and reducing the temperature after defoaming;
(5) cooling to 75 ℃, adding the phase D component, and homogenizing at 3200r/min for 2 minutes until the phase D component is uniform;
(6) cooling to below 45 ℃, adding the E phase component which is mixed and dispersed uniformly in advance, sequentially adding the raw materials of the F phase component and the G phase component, fully and uniformly stirring, and cooling to room temperature to obtain the eye cream.
The prepared eye cream is milky cream, and the pH value is measured to be 5.7 after the eye cream is diluted by water (1:10 aqueous solution); viscosity (25 ℃, mPa.s) 58530 (rotor # 4, 6 rpm/min);
heat resistance (45. + -. 2 ℃): recovering room temperature for 3 months without oil-water separation and coarsening;
cold resistance (-17 + -2 ℃): recovering room temperature for 3 months without oil-water separation and coarsening;
cycle test (45 ℃, ambient temperature, -17 ℃):3 cycles (standing at 45 ℃ for 24h, standing at normal temperature for 24h, finally turning to-17 ℃ and standing for 24h, and circulating for 3 times), and is qualified.
Example 2
The embodiment provides eye cream and a preparation method thereof.
The eye cream comprises the following components in percentage by mass (see table 1):
phase A: montanov 2022.00%, polydimethylsiloxane 2.00%, ethylhexyl palmitate 5.00%, dipentaerythritol hexacaprylate/hexacaprate 2.00%;
phase B: 0.50% of tocopherol acetate;
and C phase: deionized water (to 100%), sodium hyaluronate 0.05%, ammonium acryloyldimethyl taurate/VP copolymer 0.60%, allantoin 0.10%, butanediol 5.00%, propylene glycol 1.00%;
phase D: GI CD-92.00%, PMX-14031.00%, SEPIGEL 3050.50%, cyclopentadimethylsiloxane 5.00%;
phase E: 0.20 percent of starch aluminum octenyl succinate and 0.50 percent of propylene glycol;
and (3) phase F: hydrolyzed oat protein 5.00%, dipeptide diaminobutyrylbenzylamide diacetate 4.00%, plant extract 3.00%, Irriguard (Summinck) 1.00%, and white fungus extract 2.00%; the plant extract of the present example was prepared by mixing the following materials in a mass ratio of 1: 8: 10: 6: 12, a composition of angelica root extract, notoginseng root extract, astragalus membranaceus root extract, ligustrum lucidum seed extract, and licorice root extract;
phase G: 0.60 percent of phenoxyethanol and 0.10 percent of essence.
The preparation method of the eye cream comprises the following steps:
(1) uniformly mixing the raw materials of the phase A component, heating to 80 ℃, stirring and melting into liquid, and preserving heat for later use;
(2) in the phase C component, after the powdery raw materials are uniformly dispersed by butanediol and propylene glycol, adding water and stirring, heating to 82 ℃ until the powdery raw materials are completely and uniformly dissolved, preserving heat and defoaming for later use;
(3) adding the phase B component into the phase A component, and heating to 80 ℃;
(4) starting homogenization, slowly adding the phase C component into the mixed component of the phase A and the phase B, homogenizing for 5 minutes at 2200r/min until complete and uniform emulsification is realized, and reducing the temperature after defoaming;
(5) cooling to 70 ℃, adding the phase D component, and homogenizing at 3500r/min for 2 minutes until the phase D component is uniform;
(6) cooling to below 45 ℃, adding the E phase component which is mixed and dispersed uniformly in advance, sequentially adding the raw materials of the F phase component and the G phase component, fully and uniformly stirring, and cooling to room temperature to obtain the eye cream.
The prepared eye cream is milky cream, and the pH value is measured to be 5.9 after the eye cream is diluted by water (1:10 aqueous solution); viscosity (25 ℃, mPa.s) was 58600 (rotor # 4, 6 rpm/min);
heat resistance (45. + -. 2 ℃): recovering room temperature for 3 months without oil-water separation and coarsening;
cold resistance (-17 + -2 ℃): recovering room temperature for 3 months without oil-water separation and coarsening;
cycle test (45 ℃, ambient temperature, -17 ℃):3 cycles (standing at 45 ℃ for 24h, standing at normal temperature for 24h, finally turning to-17 ℃ and standing for 24h, and circulating for 3 times), and is qualified.
Example 3
The embodiment provides eye cream and a preparation method thereof.
The eye cream comprises the following components in percentage by mass (see table 1):
phase A: montanov 2021.00%, polydimethylsiloxane 3.00%, ethylhexyl palmitate 2.00%, dipentaerythritol hexacaprylate/hexacaprate 7.00%;
phase B: 2.00% of tocopherol acetate;
and C phase: deionized water (to 100%), sodium hyaluronate 0.08%, ammonium acryloyldimethyl taurate/VP copolymer 0.20%, allantoin 0.15%, butanediol 2.00%, propylene glycol 2.00%;
phase D: GI CD-95.00%, PMX-14030.60%, SEPIGEL 3051.00%, cyclopentadimethylsiloxane 8.00%;
phase E: 1.00 percent of starch aluminum octenyl succinate and 3.00 percent of propylene glycol;
and (3) phase F: 0.10% of hydrolyzed oat protein, 7.00% of dipeptide diaminobutyrylbenzylamide diacetate, 2.00% of plant extract, 0.30% of Irriguard (Summinck), and 5.00% of tremella extract; the plant extract of the present example was prepared by mixing the following materials in a mass ratio of 1: 5: 7: 4: 10, a composition of angelica root extract, notoginseng root extract, astragalus membranaceus root extract, ligustrum lucidum seed extract, and licorice root extract;
phase G: 0.50 percent of phenoxyethanol and 0.20 percent of essence.
The preparation method of the eye cream comprises the following steps:
(1) uniformly mixing the raw materials of the phase A component, heating to 78 ℃, stirring and melting into liquid, and preserving heat for later use;
(2) in the phase C component, after the powdery raw materials are uniformly dispersed by butanediol and propylene glycol, adding water and stirring, heating to 82 ℃ until the powdery raw materials are completely and uniformly dissolved, preserving heat and defoaming for later use;
(3) adding the phase B component into the phase A component, and heating to 78 ℃;
(4) starting homogenization, slowly adding the phase C component into the mixed component of the phase A and the phase B, homogenizing at 2000r/min for 10 minutes until complete and uniform emulsification is realized, and reducing the temperature after defoaming;
(5) cooling to 70 ℃, adding the phase D component, and homogenizing at 3200r/min for 3 minutes until the phase D component is uniform;
(6) cooling to below 45 ℃, adding the E phase component which is mixed and dispersed uniformly in advance, sequentially adding the raw materials of the F phase component and the G phase component, fully and uniformly stirring, and cooling to room temperature to obtain the eye cream.
The prepared eye cream is milky cream, and the pH value is measured to be 5.5 after the eye cream is diluted by water (1:10 aqueous solution); viscosity (25 ℃, mPa.s) 58680 (rotor # 4, 6 rpm/min);
heat resistance (45. + -. 2 ℃): recovering room temperature for 3 months without oil-water separation and coarsening;
cold resistance (-17 + -2 ℃): recovering room temperature for 3 months without oil-water separation and coarsening;
cycle test (45 ℃, ambient temperature, -17 ℃):3 cycles (standing at 45 ℃ for 24h, standing at normal temperature for 24h, finally turning to-17 ℃ and standing for 24h, and circulating for 3 times), and is qualified.
Example 4
The embodiment provides eye cream and a preparation method thereof.
The eye cream comprises the following components in percentage by mass (see table 1):
phase A: montanov 2024.00%, polydimethylsiloxane 1.50%, ethylhexyl palmitate 1.00%, dipentaerythritol hexacaprylate/hexacaprate 5.00%;
phase B: 0.10% of tocopherol acetate;
and C phase: deionized water (to 100%), sodium hyaluronate 0.01%, ammonium acryloyldimethyl taurate/VP copolymer 0.80%, allantoin 0.01%, butanediol 1.00%, propylene glycol 0.60%;
phase D: GI CD-91.00%, PMX-14035.00%, SEPIGEL 3050.10%, cyclopentadimethylsiloxane 6.00%;
phase E: 0.02% of starch aluminum octenyl succinate and 0.80% of propylene glycol;
and (3) phase F: 0.80% of hydrolyzed oat protein, 6.00% of dipeptide diaminobutyrylbenzylamide diacetate, 7.00% of plant extract, 4.00% of Irriguard (Summinck), and 1.00% of tremella extract; the plant extract of the present example was prepared by mixing the following materials in a mass ratio of 5: 3: 5: 2: 8, a combination of angelica root extract, notoginseng root extract, astragalus membranaceus root extract, privet seed extract and licorice root extract;
phase G: 0.40 percent of phenoxyethanol and 0.03 percent of essence.
The preparation method of the eye cream comprises the following steps:
(1) uniformly mixing the raw materials of the phase A component, heating to 80 ℃, stirring and melting into liquid, and preserving heat for later use;
(2) in the phase C component, after the powdery raw materials are uniformly dispersed by butanediol and propylene glycol, adding water and stirring, heating to 80 ℃ until the powdery raw materials are completely and uniformly dissolved, preserving heat and defoaming for later use;
(3) adding the phase B component into the phase A component, and heating to 80 ℃;
(4) starting homogenization, slowly adding the phase C component into the mixed component of the phase A and the phase B, homogenizing for 8 minutes at 2200r/min until complete and uniform emulsification is realized, and reducing the temperature after defoaming;
(5) cooling to 75 ℃, adding the phase D component, and homogenizing at 3000r/min for 3 minutes until the mixture is uniform;
(6) cooling to below 45 ℃, adding the E phase component which is mixed and dispersed uniformly in advance, sequentially adding the raw materials of the F phase component and the G phase component, fully and uniformly stirring, and cooling to room temperature to obtain the eye cream.
The eye cream prepared is milky cream, and the pH value is measured to be 6.2 after the eye cream is diluted by water (1:10 aqueous solution); viscosity (25 ℃, mPa.s) was 58650(4# rotor, 6 rpm/min);
heat resistance (45. + -. 2 ℃): recovering room temperature for 3 months without oil-water separation and coarsening;
cold resistance (-17 + -2 ℃): recovering room temperature for 3 months without oil-water separation and coarsening;
cycle test (45 ℃, ambient temperature, -17 ℃):3 cycles (standing at 45 ℃ for 24h, standing at normal temperature for 24h, finally turning to-17 ℃ and standing for 24h, and circulating for 3 times), and is qualified.
Example 5
The embodiment provides eye cream and a preparation method thereof.
The eye cream comprises the following components in percentage by mass (see table 1):
phase A: montanov 2023.00%, polydimethylsiloxane 4.00%, ethylhexyl palmitate 3.00%, dipentaerythritol hexacaprylate/hexacaprate 0.30%;
phase B: 3.00% of tocopherol acetate;
and C phase: deionized water (to 100%), sodium hyaluronate 0.03%, ammonium acryloyldimethyl taurate/VP copolymer 0.90%, allantoin 0.20%, butanediol 3.00%, propylene glycol 1.50%;
phase D: GI CD-90.20%, PMX-14032.00%, SEPIGEL 3050.60%, cyclopentadimethylsiloxane 1.00%;
phase E: 0.08 percent of starch aluminum octenyl succinate and 0.10 percent of propylene glycol;
and (3) phase F: hydrolyzed oat protein 4.00%, dipeptide diaminobutyrylbenzylamide diacetate 5.00%, plant extract 4.00%, Irriguard (Summinck) 3.00%, and white fungus extract 0.80%; the plant extract of the present example was prepared by mixing the following materials in a mass ratio of 5: 8: 10: 6: 12, a composition of angelica root extract, notoginseng root extract, astragalus membranaceus root extract, ligustrum lucidum seed extract, and licorice root extract;
phase G: 0.30 percent of phenoxyethanol and 0.06 percent of essence.
The preparation method of the eye cream comprises the following steps:
(1) uniformly mixing the raw materials of the phase A component, heating to 78 ℃, stirring and melting into liquid, and preserving heat for later use;
(2) in the phase C component, after the powdery raw materials are uniformly dispersed by butanediol and propylene glycol, adding water and stirring, heating to 80 ℃ until the powdery raw materials are completely and uniformly dissolved, preserving heat and defoaming for later use;
(3) adding the phase B component into the phase A component, and heating to 80 ℃;
(4) starting homogenization, slowly adding the phase C component into the mixed component of the phase A and the phase B, homogenizing for 8 minutes at 2200r/min until complete and uniform emulsification is realized, and reducing the temperature after defoaming;
(5) cooling to 72 ℃, adding the phase D component, and homogenizing at 3200r/min for 3 minutes until the phase D component is uniform;
(6) cooling to below 45 ℃, adding the E phase component which is mixed and dispersed uniformly in advance, sequentially adding the raw materials of the F phase component and the G phase component, fully and uniformly stirring, and cooling to room temperature to obtain the eye cream.
The prepared eye cream is milky cream, and the pH value is measured to be 5.8 after the eye cream is diluted by water (1:10 aqueous solution); viscosity (25 ℃, mPa.s) 58590 (rotor # 4, 6 rpm/min);
heat resistance (45. + -. 2 ℃): recovering room temperature for 3 months without oil-water separation and coarsening;
cold resistance (-17 + -2 ℃): recovering room temperature for 3 months without oil-water separation and coarsening;
cycle test (45 ℃, ambient temperature, -17 ℃):3 cycles (standing at 45 ℃ for 24h, standing at normal temperature for 24h, finally turning to-17 ℃ and standing for 24h, and circulating for 3 times), and is qualified.
Example 6
The embodiment provides eye cream and a preparation method thereof.
The eye cream comprises the following components in percentage by mass (see table 1):
phase A: montanov 2022.50%, polydimethylsiloxane 2.00%, ethylhexyl palmitate 7.00%, dipentaerythritol hexacaprylate/hexacaprate 1.00%;
phase B: 2.50% of tocopherol acetate;
and C phase: deionized water (to 100%), sodium hyaluronate 0.06%, ammonium acryloyldimethyl taurate/VP copolymer 0.40%, allantoin 0.23%, butanediol 7.00%, propylene glycol 0.10%;
phase D: GI CD-93.00%, PMX-14030.10%, SEPIGEL 3051.50%, cyclopentadimethylsiloxane 3.00%;
phase E: 0.40% of starch aluminum octenyl succinate and 1.50% of propylene glycol;
and (3) phase F: 2.00% of hydrolyzed oat protein, 1.00% of dipeptide diaminobutyrylbenzylamide diacetate, 5.00% of plant extract, 1.50% of Irriguard (Summinck), and 4.00% of tremella extract; the plant extract of the present example was prepared by mixing the following materials in a mass ratio of 5: 5: 7: 4: 10, a composition of angelica root extract, notoginseng root extract, astragalus membranaceus root extract, ligustrum lucidum seed extract, and licorice root extract;
phase G: 0.50 percent of phenoxyethanol and 0.10 percent of essence.
The preparation method of the eye cream comprises the following steps:
(1) uniformly mixing the raw materials of the phase A component, heating to 80 ℃, stirring and melting into liquid, and preserving heat for later use;
(2) in the phase C component, after the powdery raw materials are uniformly dispersed by butanediol and propylene glycol, adding water and stirring, heating to 82 ℃ until the powdery raw materials are completely and uniformly dissolved, preserving heat and defoaming for later use;
(3) adding the phase B component into the phase A component, and heating to 80 ℃;
(4) starting homogenization, slowly adding the phase C component into the mixed component of the phase A and the phase B, homogenizing for 5 minutes at 2200r/min until complete and uniform emulsification is realized, and reducing the temperature after defoaming;
(5) cooling to 75 ℃, adding the phase D component, and homogenizing at 3400r/min for 2 minutes until the mixture is uniform;
(6) cooling to below 45 ℃, adding the E phase component which is mixed and dispersed uniformly in advance, sequentially adding the raw materials of the F phase component and the G phase component, fully and uniformly stirring, and cooling to room temperature to obtain the eye cream.
The eye cream prepared is milky cream, and the pH value is 6.5 after the eye cream is diluted by water (1:10 aqueous solution); viscosity (25 ℃, mPa.s) 58620 (rotor # 4, 6 rpm/min);
the heat resistance (45 plus or minus 2 ℃) is 3 months, the room temperature is recovered, and the phenomena of oil-water separation and coarsening are avoided;
cold resistance (-17 + -2 ℃): recovering room temperature for 3 months without oil-water separation and coarsening;
cycle test (45 ℃, ambient temperature, -17 ℃):3 cycles (standing at 45 ℃ for 24h, standing at normal temperature for 24h, finally turning to-17 ℃ and standing for 24h, and circulating for 3 times), and is qualified.
TABLE 1
Comparative example 1
The comparative example is a comparative example of example 2, and the eye cream of the comparative example differs from the eye cream of example 2 mainly in that: the eye cream of this comparative example did not have hydrolyzed oat protein added.
Comparative example 2
The comparative example is a comparative example of example 2, and the eye cream of the comparative example differs from the eye cream of example 2 mainly in that: the eye cream of this comparative example did not contain dipeptide diaminobutyrylbenzylamide diacetate.
Comparative example 3
The comparative example is a comparative example of example 2, and the eye cream of the comparative example differs from the eye cream of example 2 mainly in that: the eye cream of this comparative example did not have plant extracts added.
Comparative example 4
The comparative example is a comparative example of example 2, and the eye cream of the comparative example differs from the eye cream of example 2 mainly in that: the eye cream of the present comparative example had 9 mass%, 0.5 mass% and 0.5 mass% of hydrolyzed oat protein, dipeptide diaminobutyrylbenzylamide diacetate and plant extract, respectively.
Comparative example 5
The comparative example is a comparative example of example 2, and the eye cream of the comparative example differs from the eye cream of example 2 mainly in that: the eye cream of the present comparative example contained no angelica root extract, sanchi root extract and privet seed extract in the plant extracts.
Performance testing
110 healthy skin volunteers were randomly selected and tested, one group was taken for 10 persons, each group was taken as a unit, the eye cream samples of the test examples 1-6 and the eye cream samples of the comparative examples 1-5 were respectively used, the subjects adhered to the eye cream samples once a day in the morning and at night for 30 consecutive days, and the test results were averaged.
Firstly, the moisture content (i.e. the moisture degree) of the skin is measured by a skin moisture tester, the moisture degree increase rate of △ a% ((a 2-a1)/a1 × 100%), a1 is the result of the test data before use, and a2 is the result of the test data after use.
Second, the skin elasticity was measured using a revisometer rv600 probe using a skin elasticity tester MPA580 from CK, germany, and the skin elasticity improvement rate of △ a% ((a 2-a1)/a1 × 100%), a1 is the test data before use, and a2 is the test data after use.
And thirdly, scoring the volunteers according to the experience feeling of the volunteers and the observation of the improvement of qi and blood within 1 to 10 by using experience degree scoring, permeability scoring and qi and blood improvement scoring, and finally averaging. The scoring criteria were graded using a gradient: 0-3 minutes, the effect is extremely poor; 3-6 points, the effect is poor; the effect is general in 6-8 points; 8-9 minutes, the effect is good; 9-10 minutes, the effect is excellent.
And measuring the tightness, the fineness and the wrinkles by using a skin detector, specifically using a Visia skin detector, wherein the test position of the wrinkles is an canthus, the tightness effective rate △ A% ((A2-A1)/A1 × 100%), A1 is a test data result before use, A2 is a test data result after use, the fineness improvement rate △ A% ((A2-A1)/A1 × 100%), A1 is a test data result before use, and A2 is a test data result after use.
Fifth, Permeability test experiment
In the use process of the eye cream, allantoin penetrates deep into the dermis tissue to play a deep moisturizing role on the skin, so that the allantoin is used as a test object of permeability.
(1) Taking 10 Kunming mice with similar body weight (within the range of 30-35 g), numbering 1-10, and depilating the skin of the chest and abdomen of the mice with 6 wt% of sodium sulfide;
(2) the 10 eye cream samples of examples 1 to 6 and comparative examples 1 to 5 were sequentially applied, and two portions (2.0mm × 1.5mm) were randomly confirmed to the chest and abdomen of the No. 1 to 10 mouse, and 1.0g of the corresponding eye cream sample was applied;
(3) after 30min, the mouse is killed by breaking the neck, the chest and abdomen skin coated with the eye cream sample is taken down, and the chest and abdomen skin which is not coated with the eye cream sample and has the same size is taken as a blank control group;
(4) removing epidermis from the chest and abdomen skin of the mouse, grinding the dermal tissue to be chyle, adding 5mL of absolute ethyl alcohol, mixing, centrifuging at 8000r/min for 15min, collecting the supernatant, and purifying with LC-9A high performance liquid chromatography (Shimadzu, Japan) [ C18 ] column at 25 deg.C with ethanol as mobile phase: allantoin content was determined at a flow rate of 1.0mL/min, water 10:90, detection wavelength of 224 nm.
Wherein, the content of the blank control group is 100 percent, and the result is the average value of the test results of dermal tissues of two different parts.
The test results are shown in tables 2, 3 and 4.
TABLE 2
| Test items | Rate of increase in skin elasticity | Water wettability improvement rate | Effective rate of tightening | Permeability rate of penetration |
| Example 1 | 81.8％ | 36.2％ | 78.6％ | 485％ |
| Example 2 | 84.3％ | 39.4％ | 82.4％ | 528％ |
| Example 3 | 79.1％ | 35.8％ | 77.3％ | 490％ |
| Example 4 | 80.4％ | 38.1％ | 86.8％ | 500％ |
| Example 5 | 78.6％ | 34.9％ | 76.9％ | 490％ |
| Example 6 | 82.7％ | 37.5％ | 80.5％ | 510％ |
| Comparative example 1 | 33.2％ | 14.8％ | 30.3％ | 320％ |
| Comparative example 2 | 55.3％ | 29.6％ | 76.4％ | 248％ |
| Comparative example 3 | 46.5％ | 21.2％ | 69.3％ | 220％ |
| Comparative example 4 | 59.2％ | 33.1％ | 68.1％ | 425％ |
| Comparative example 5 | 23.4％ | 9.3％ | 25.8％ | 160％ |
TABLE 3
| Test items | Usage experience scoring | Permeability score | Score for improvement of qi and blood |
| Example 1 | 9.2 | 9.0 | 8.8 |
| Example 2 | 9.5 | 9.5 | 9.0 |
| Example 3 | 8.8 | 9.0 | 8.5 |
| Example 4 | 9.2 | 9.5 | 8.7 |
| Example 5 | 8.6 | 9.0 | 8.5 |
| Example 6 | 9.0 | 9.2 | 8.6 |
| Comparative example 1 | 4.5 | 7.5 | 6.0 |
| Comparative example 2 | 6.5 | 4.5 | 6.0 |
| Comparative example 3 | 6.5 | 4.0 | 5.0 |
| Comparative example 4 | 7.5 | 7.0 | 8.4 |
| Comparative example 5 | 3.5 | 2.0 | 4.0 |
TABLE 4
As can be seen from tables 2 to 4: (1) the eye creams of examples 1 to 6 have good permeability as a whole and can play a role in deep moisturizing; moreover, the eye mask has good permeability, and can also make eye skin fine, compact and moist, improve skin elasticity, reduce wrinkles and improve qi and blood. (2) The effects of examples 1 to 6 are due to the comparative examples as a whole, which shows that it is crucial to properly match plant extracts with hydrolysed oat protein and dipeptide diaminobutyrylbenzylamide diacetate.
The technical features of the embodiments described above may be arbitrarily combined, and for the sake of brevity, all possible combinations of the technical features in the embodiments described above are not described, but should be considered as being within the scope of the present specification as long as there is no contradiction between the combinations of the technical features.
The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.
Claims (10)
1. A skin care composition is characterized by comprising the following components in percentage by mass (0.1-7): (1-7): (1-7) the hydrolyzed avenin, dipeptide diaminobutyrylbenzylamide diacetate, and plant extracts comprising angelica root extract, notoginseng root extract, astragalus membranaceus root extract, ligustrum lucidum ait seed extract, and licorice root extract.
2. The skin care composition according to claim 1, wherein the plant extract comprises the following components in a mass ratio of (1-5): (3-8): (5-10): (2-6): (8-12) Angelica root extract, Panax notoginseng root extract, Astragalus membranaceus root extract, Ligustrum lucidum seed extract, and Glycyrrhiza uralensis root extract.
3. Use of a skin care composition according to claim 1 or 2 in the preparation of a skin care product.
4. Use according to claim 3, wherein the skin-care product is an eye cream.
5. The eye cream is characterized by comprising water and the following components in percentage by mass:
6. the eye cream as claimed in claim 5, wherein the other functional auxiliary agents comprise the following components in percentage by mass:
7. the eye cream of claim 6, wherein the antioxidant is tocopherol acetate; the preservative is phenoxyethanol; or/and the anti-allergy agent is at least one of astragalus membranaceus root extract, divaricate saposhnikovia root extract, calendula extract, albizia flower extract and gastrodia elata root extract; or/and the bactericide is allantoin.
8. The eye cream according to any one of claims 5 to 7, wherein the emulsifier is an alkyl glycoside type liquid crystal emulsifier; or/and the emollient is selected from at least one of polydimethylsiloxane, ethylhexyl palmitate, dipentaerythritol hexacaprylate/hexadecanoate, cyclopentadimethylsiloxane, stearyloxymethylsiloxane/polydimethylsiloxane copolymer, polydimethylsiloxane, dimethicone alcohol, and cyclopentadimethylsiloxane; or/and the skin feel modifier is aluminum starch octenyl succinate.
9. The eye cream according to any one of claims 5 to 7, wherein the moisturizer is selected from at least one of sodium hyaluronate, butylene glycol, propylene glycol and tremella extract; or/and the thickening agent is selected from at least one of acryloyl dimethyl ammonium taurate/VP copolymer, polyacrylamide, C13-14 isoparaffin and laureth-7.
10. The method for preparing an eye cream according to any one of claims 5 to 7, comprising the steps of:
(1) mixing the emulsifier and part of the emollient to prepare a phase A; taking part of the other functional auxiliary agents to prepare a phase B;
(2) adding the phase B to the phase A and mixing;
(3) mixing water, part of the humectant, part of the thickener and the other functional auxiliary agent to prepare a phase C; adding the phase C into the product obtained in the step (2), and mixing;
(4) mixing the rest of the emollient and the rest of the thickener to prepare a phase D; adding the phase D into the product obtained in the step (3), and mixing;
(5) mixing the skin feeling regulator and the other part of the humectant to prepare phase E; mixing the skin care composition of claim 1 or 2, the remainder of the moisturizer, and a further portion of the other functional adjuvants to prepare phase F; mixing the rest of the other functional additives to prepare a G phase; adding the phase E, the phase F and the phase G to the product obtained in the step (4), and mixing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911024883.9A CN110960436A (en) | 2019-10-25 | 2019-10-25 | Skin care composition, eye cream and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911024883.9A CN110960436A (en) | 2019-10-25 | 2019-10-25 | Skin care composition, eye cream and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110960436A true CN110960436A (en) | 2020-04-07 |
Family
ID=70029834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911024883.9A Pending CN110960436A (en) | 2019-10-25 | 2019-10-25 | Skin care composition, eye cream and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110960436A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111568831A (en) * | 2020-06-19 | 2020-08-25 | 上海相宜本草化妆品股份有限公司 | Composition of Chinese herbal medicine extract for skin cosmetics and preparation method thereof |
| CN113908110A (en) * | 2021-12-01 | 2022-01-11 | 易生彬 | Anti-aging traditional Chinese medicine skin care composition for periocular period and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107233246A (en) * | 2017-06-12 | 2017-10-10 | 广州劳莎生物科技有限公司 | A kind of eye cream and preparation method thereof |
| CN107693391A (en) * | 2017-11-21 | 2018-02-16 | 上海合轩品牌管理有限公司 | A kind of anti-wrinkle eye cream and preparation method thereof |
| CN108670919A (en) * | 2018-06-13 | 2018-10-19 | 北京日光旭升精细化工技术研究所 | Natural crease-resistant smoothing wrinkle composition and its application and the eye cream comprising the composition |
| CN109528612A (en) * | 2019-01-18 | 2019-03-29 | 广州市普高管理咨询有限公司 | Crease-resistant tightening cosmetic composition, lotion and its preparation method and application |
-
2019
- 2019-10-25 CN CN201911024883.9A patent/CN110960436A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107233246A (en) * | 2017-06-12 | 2017-10-10 | 广州劳莎生物科技有限公司 | A kind of eye cream and preparation method thereof |
| CN107693391A (en) * | 2017-11-21 | 2018-02-16 | 上海合轩品牌管理有限公司 | A kind of anti-wrinkle eye cream and preparation method thereof |
| CN108670919A (en) * | 2018-06-13 | 2018-10-19 | 北京日光旭升精细化工技术研究所 | Natural crease-resistant smoothing wrinkle composition and its application and the eye cream comprising the composition |
| CN109528612A (en) * | 2019-01-18 | 2019-03-29 | 广州市普高管理咨询有限公司 | Crease-resistant tightening cosmetic composition, lotion and its preparation method and application |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111568831A (en) * | 2020-06-19 | 2020-08-25 | 上海相宜本草化妆品股份有限公司 | Composition of Chinese herbal medicine extract for skin cosmetics and preparation method thereof |
| CN111568831B (en) * | 2020-06-19 | 2023-02-03 | 上海相宜本草化妆品股份有限公司 | Composition of Chinese herbal medicine extract for skin cosmetics and preparation method thereof |
| CN113908110A (en) * | 2021-12-01 | 2022-01-11 | 易生彬 | Anti-aging traditional Chinese medicine skin care composition for periocular period and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109528603A (en) | Lightening compositions, whitening brightening cream comprising lightening compositions and preparation method thereof | |
| CN108685800B (en) | Composition for promoting estrogen secretion, emulsion and preparation method thereof | |
| CN103976905A (en) | Plant extract liquid mixture with antiphlogosis and antianaphylaxis effect | |
| CN105147991A (en) | Traditional Chinese medicine combination for inhibiting melanin generation and preparation method and application thereof | |
| CN112043661B (en) | Whitening aloe gel and preparation method thereof | |
| CN106265164A (en) | There is compositions of hair growth promoting, scalp maintenance, moisture-keeping efficacy and preparation method thereof | |
| CN111297756B (en) | Essence with moistening and moisturizing and anti-allergy effects and preparation method thereof | |
| CN112438925A (en) | Anti-allergy repairing composition and application thereof | |
| CN110882201A (en) | Itching-relieving skin-care cream and preparation method thereof | |
| CN112826867A (en) | Traditional Chinese medicine composition for relieving itching and removing dandruff and application thereof in cosmetics | |
| CN113288836A (en) | Preparation method and application of acne-removing compound | |
| CN110859791A (en) | Skin whitening composition, application thereof and skin whitening mask | |
| CN110960436A (en) | Skin care composition, eye cream and preparation method thereof | |
| CN114983914A (en) | Preparation method of whitening skin care product | |
| CN109700733A (en) | Plant mask and preparation method thereof | |
| CN114432225A (en) | Sunscreen skin care product and preparation method thereof | |
| CN112107522A (en) | Whitening composition, whitening mask and preparation method thereof | |
| CN108836925A (en) | It is a kind of to resist the composition for doing quick Chinese medical extract and preparation method and the application in cosmetics | |
| CN105878107A (en) | Skin-care product composition for sensitive skin | |
| CN106309911B (en) | Anti-aging traditional Chinese medicine composition and preparation method thereof | |
| CN107823004A (en) | Plant composition with anti-sunlight function and its application in sunscreen product | |
| CN104523530A (en) | Anti-aging facial mask and preparation method thereof | |
| CN115778870B (en) | Anti-wrinkle anti-aging composition, and preparation method and application thereof | |
| CN110917105A (en) | Allergy-relieving cosmetic composition and preparation method thereof | |
| CN110974775A (en) | Allergy-relieving composition containing nostoc sphaeroides and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200407 |
|
| RJ01 | Rejection of invention patent application after publication |